Sublocade is a long-acting form of injectable buprenorphine that has shown promise for patients with opioid use disorder and adherence challenges. Here, we cover recent updates to prescribing guidelines that may expand its clinical utility.
GLP-1 agonists have taken the world by storm, especially for weight loss—but emerging evidence suggests they may also play a role in addiction treatment. In this article, we review the latest research to highlight when these medications might offer the greatest benefit for patients with substance use disorders.
Xylazine is a non-opioid sedative commonly added surreptitiously to illicit opioids. One particularly challenging adverse effect of xylazine exposure is the development of peripheral wounds, some of which can be severe, necessitating surgical intervention and even amputation. In this interview, Dr. D’Orazio teaches us how these wounds might be caused, how to discuss them with your patients, and the best treatment approach.
Substance use is associated with many dental problems, some of which can even be life threatening. Here, Dr. Ouanounou discusses which specific dental issues addiction treatment providers need to be on the lookout for. He covers the basics of dental examination and teaches us when referral to specialty care is warranted.
Injectable naltrexone can be an effective treatment for opioid use disorder, but it requires complete abstinence before initiation—a process that can take more than a week and cause significant discomfort. Here, researchers evaluate a new protocol designed to accelerate this induction period and improve patient access.
Hepatitis B and C are highly prevalent in people who use drugs and can result in significant morbidity and mortality due to progressive liver disease. In this article, we cover all the basics, including screening, symptoms, and relevant laboratory testing. We give tips to provide your patients on hepatitis prevention and when to refer them to specialists for treatment.
Dr. Capurso is the Assistant Director of Addiction Services at Connecticut Valley Hospital and an associate clinical professor of psychiatry at the Yale University School of Medicine. Prior to joining Connecticut Valley Hospital, he was the medical director of the Detoxification & Addiction Stabilization Service and the Psychosocial Residential Rehabilitation Program at the West Haven Veterans Administration Hospital. He completed medical school, psychiatry residency, and addiction psychiatry fellowship at Yale.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
